Pain Management, Pharmacologic, and Integrative Care

Pain Management, Pharmacologic, and Integrative Care

Pain Assessment

Cancer pain arises from tumor invasion, bone metastases, nerve compression, surgery, radiation, mucositis, procedures, lymphedema, and chemo-induced neuropathy. Assess location, intensity, quality, duration, pattern, aggravating and relieving factors, breakthrough episodes, current medications, allergies, renal and hepatic function, sedation, bowel pattern, sleep, mood, function, substance-use history, and the patient's acceptable pain goal. Use one scale consistently, but never reduce pain to a number, ask what the pain prevents the patient from doing.

New severe pain, pain with neurologic deficits, headache during thrombocytopenia, or pain at an infusion site may be an emergency.

The WHO Ladder and Opioid Dosing

The WHO analgesic ladder guides selection: Step 1 nonopioids (acetaminophen, NSAIDs) +/- adjuvants; Step 2 weak opioids for mild-moderate pain; Step 3 strong opioids (morphine, hydromorphone, oxycodone, fentanyl) for moderate-severe pain, with adjuvants at every step. For persistent cancer pain, give a scheduled long-acting (around-the-clock) opioid plus a short-acting breakthrough (rescue) dose. The rescue dose is typically about 10-20% of the total 24-hour oral morphine equivalent, given as immediate-release. Pure opioid agonists have no ceiling dose, so the limit is set by side effects, not a maximum number.

When rotating opioids, use equianalgesic tables (for example, ~10 mg IV morphine ~ 30 mg oral morphine ~ 1.5 mg IV hydromorphone), then reduce the calculated new dose by 25-50% for incomplete cross-tolerance. Giving the full equianalgesic dose risks overdose. Reassess sooner for IV than oral routes.

Safety Monitoring and Constipation

Monitor for excessive sedation, confusion, slowed respirations, myoclonus, falls, nausea, pruritus, and urinary retention; sedation precedes clinically significant respiratory depression, so a rising sedation score is the early warning. Opioid-induced constipation is universal and predictable: prevent it with a scheduled stimulant laxative (senna) plus a softener (docusate), not a softener alone, and never with bulk-forming fiber that can worsen impaction. Escalate uncontrolled or rapidly worsening pain, new neurologic findings, suspected fracture, severe sedation, or respiratory depression.

Refer to palliative care for complex or refractory pain.

Disease-Directed Options and Integrative Care

Some pain responds best when the driver is treated: bone-metastasis pain may improve with palliative radiation, bisphosphonates or denosumab, or orthopedic stabilization; neuropathic pain often needs adjuvants (gabapentin, pregabalin, duloxetine) rather than ever-higher opioids alone. Integrative modalities, relaxation breathing, guided imagery, music therapy, mindfulness, gentle movement, acupuncture, and adapted massage, can support coping, sleep, anxiety, and pain when used alongside prescribed care.

Safety rules: avoid massage over tumors, thrombosis, fragile skin, or severe thrombocytopenia; avoid acupuncture in severe neutropenia or thrombocytopenia without oncology approval; and ask nonjudgmentally about herbal supplements, which can interact with chemotherapy, anticoagulants, and anesthesia, routing questions to pharmacy. Patients underreport pain from fear of addiction, progression, or losing treatment; teach that early reporting prevents crises, and confirm dose timing, rescue limits, bowel regimen, and driving restrictions with teach-back.

Routes, Patient-Controlled Analgesia, and Special Situations

Route selection follows the pain pattern and the patient's ability to swallow. The oral route is preferred when feasible, but mucositis, obstruction, vomiting, or rapidly escalating pain may require IV, subcutaneous, or transdermal delivery. Transdermal fentanyl is reserved for opioid-tolerant patients with stable pain because it has a slow onset (12-24 hours to steady effect) and a long offset, making it unsafe for opioid-naive or unstable acute pain.

Patient-controlled analgesia (PCA) lets the patient self-administer small IV doses within preset limits; the nurse teaches that only the patient presses the button (never family members, which has caused fatal oversedation), monitors the sedation score and respiratory rate, and recognizes that the lockout interval and basal-versus-demand settings are prescriber decisions. Methadone has a long, variable half-life and complex equianalgesic conversion, so it is managed conservatively and usually by clinicians experienced with it.

Adjuvants, Tolerance, and Advocacy

Adjuvant analgesics treat pain that opioids alone manage poorly. Gabapentin, pregabalin, and duloxetine target neuropathic burning and shooting pain; corticosteroids reduce pain from nerve or spinal-cord compression and capsular stretch; bisphosphonates and denosumab reduce bone-metastasis pain and skeletal events. The nurse separates tolerance (needing more drug for the same effect), physical dependence (withdrawal if stopped abruptly), and addiction (compulsive use despite harm), because conflating them leads to undertreatment of legitimate cancer pain.

Patients on chronic opioids should taper rather than stop abruptly, and a sudden increase in opioid need usually signals disease progression or a new complication that deserves evaluation, not a label of drug-seeking. The nurse advocates by describing the pain pattern, functional impact, and medication response clearly, screening for diversion risk and safe storage and disposal without stigma, and confirming through teach-back that the patient understands the difference between the scheduled and rescue doses and exactly when to call for help.

Cultural beliefs, language, and prior experiences shape how patients express and treat pain, so the nurse assesses these factors and individualizes both the plan and the teaching rather than assuming a single approach fits everyone.